Pradžia › Leukemija › Koloradas
Leukemija klinikiniai tyrimai Koloradas
15 tyrimai dėl Leukemija ieško dalyvių vietose Koloradas.
Miestai Koloradas
Oficialus tyrimo tekstas (anglų kalba)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Colorado, Aurora
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Denver
Renkami dalyviai3 fazė
Amžius nuo 18 iki 18 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07509151First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Children's Hospital Colorado, Aurora
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-01 · NCT07586618Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Colorado Children's Hospital, Denver
Renkami dalyviai2 fazė
Amžius nuo 7 iki 25 · Visoms lytims · Atnaujinta 2026-08-19 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 19 iki 110 · Visoms lytims · Atnaujinta 2026-06-29 · NCT02012699Shwachman Diamond Syndrome Registry and Study
- Children's Hospital Colorado, Aurora
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-04-06 · NCT06056908A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT05735184Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
- Children's Hospital Colorado, Aurora
Renkami dalyviaiStebimasis tyrimas
Iki 22 metų · Visoms lytims · Atnaujinta 2026-02-05 · NCT05425992Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- University of Colorado Hospital, Aurora
Renkami dalyviai1 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-01-15 · NCT06429449Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Rocky Mountain Cancer Centers, Aurora
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-31 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Aurora
- Massive Bio SYNERGY-AI site, Denver
- Massive Bio SYNERGY-AI site, Littleton
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.